HI-Bio is formerly owned by Jeito Capital, through Jeito I, since 2021.

When did Jeito Capital acquire HI-Bio?

Jeito Capital acquired HI-Bio in 2021 and exited after 3 years.

Has HI-Bio been sold?

Yes. HI-Bio was exited in 2024 via Trade Sale.

Home/Companies/Biotech/HI-Bio

HI-Bio

Biotech·

US·Exited 2024·Held 3yr

HI-Bio is a healthcare company, headquartered in France.

Entry

2021

Hold

3yr

Exit

2024

Est. EV

–

Investor

Jeito Capital

Key facts

HQFrance

SectorHealthcare

Massachusetts-based immunology biotech (Human Immunology Biosciences) developing precision-medicine therapies; Jeito Capital backed 2021…Read full notes

See the full ownership history.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Full fund context: vintage, strategy, region

Exit details: type, year, MOIC (buyer on Pro)

Start free

Already a member? Sign in

More from Jeito I

Other portfolio companies in the same fund.

Corteria Pharmaceuticals

More PE-backed in Biotech

Comparable biotech deals from other GPs.

AdBio PartnersBelgium

Last updated April 2026 · Sourced from public filings